title: [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
abstract: OBJECTIVE
  To evaluate the prevalence of TET2 gene mutation in acute myeloid leukemia (AML) patients, and analyze their clinical characteristics and prognosis.
  
  
  METHODS
  Polymerase chain reaction (PCR) and direct sequencing were used to sequence exon 3 to 11 of TET2 gene.
  
  
  RESULTS
  Among 96 AML patients, TET2 gene mutation was detected in 13 (13.54%) patients (95%CI 6.70% - 20.38%). The median age was 54 years in mutated group and 41 years in unmutated group (P = 0.010). Mutated and unmutated patients did not significantly differ in gender, white blood cells (WBC) count at diagnosis, platelet count, PB and BM blast percentage and chromosome karyotype, excepting for hemoglobin level 84 (70 - 108) g/L in mutated group versus 70 (55 - 87) g/L in unmutated group (P = 0.032). TET2 gene mutation had no significant correlation with C-KIT, FLT3, JAK2V617F mutations, but did with NPM1 mutation. TET2 mutated patients had lower CR1 rate and 2-year overall survival than unmutated in non-M(3) patients (P < 0.05).
  
  
  CONCLUSIONS
  TET2 gene mutation is more prevalent in older AML patients and has a certain correlation with clinical characteristics and outcome. It may be a molecular marker for poor prognosis in AML.
authors: Jiangsu Institute of Hematology, Soochow University, Suzhou 215006, China.
authors: Ji-feng
authors: JF
authors: Wei
authors: Guang-hua
authors: GH
authors: Chen
authors: Hui-ying
authors: HY
authors: Qiu
authors: Cheng-cheng
authors: CC
authors: Fu
authors: Zi-xuan
authors: ZX
authors: Ding
authors: Hong
authors: H
authors: Liu
authors: Yu-feng
authors: YF
authors: Feng
authors: Su-ning
authors: SN
authors: Chen
authors: Wei-rong
authors: WR
authors: Chang
authors: De-pei
authors: DP
authors: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004252:DNA Mutational Analysis; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D005091:Exons; D005260:Female; D006801:Humans; D059785:Karyotype; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000090243:Nucleophosmin; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D055815:Young Adult
chemical_list: D004268:DNA-Binding Proteins; C000716967:NPM1 protein, human; D011518:Proto-Oncogene Proteins; D000090243:Nucleophosmin; D049308:Dioxygenases; C541081:TET2 protein, human